It is obvious that the CAR-T approach to cancer treatment is here to stay and to change the way cancer has been managed for decades. Attempts to improve the novel elegant procedure safety profile and efficacy on solid cancers are being pursued by academia as well as by biotechnology and pharmaceutical companies.

Kite Pharma’s (KITE) CAR-T therapy axicabtagene ciloleucel is an investigational therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR)to target the antigen CD19, which is a protein expressed . . .